Key Takeaways
- • Multiply Labs raised $75 million in Series B funding, bringing total capital raised to over $100 million since its 2016 founding, as the physical AI company scales automation of complex pharmaceutical manufacturing processes.
- • Dr. Patrick Soon-Shiong and NantWorks led the round, with major pharma player AstraZeneca joining as a new investor alongside Lingotto, Teradyne, and Strange Ventures.
- • Returning investors including Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund participated, signaling sustained confidence in the company's manufacturing automation platform.
Summary
Multiply Labs, a San Francisco-based physical AI company focused on automating complex manufacturing processes in pharmaceuticals, announced a $75 million Series B funding round on October 7, 2026. The capital raise brings the company's total funding to over $100 million since its 2016 inception, reflecting investor confidence in its approach to deploying artificial intelligence and automation in pharmaceutical production.
Dr. Patrick Soon-Shiong and his investment vehicle NantWorks led the Series B, with strategic participation from AstraZeneca, one of the world's largest pharmaceutical manufacturers. The round also included new investors Lingotto, Teradyne, and Strange Ventures. The presence of AstraZeneca as a new backer suggests alignment between Multiply Labs' manufacturing automation capabilities and the pharmaceutical industry's operational priorities.
The funding round received support from existing backers Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund, among others. This participation from repeat investors underscores sustained conviction in the company's ability to scale its physical AI platform and capture market opportunity in an industry where manufacturing precision and efficiency are critical competitive factors.
Dr. Patrick Soon-Shiong and his investment vehicle NantWorks led the Series B, with strategic participation from AstraZeneca, one of the world's largest pharmaceutical manufacturers. The round also included new investors Lingotto, Teradyne, and Strange Ventures. The presence of AstraZeneca as a new backer suggests alignment between Multiply Labs' manufacturing automation capabilities and the pharmaceutical industry's operational priorities.
The funding round received support from existing backers Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund, among others. This participation from repeat investors underscores sustained conviction in the company's ability to scale its physical AI platform and capture market opportunity in an industry where manufacturing precision and efficiency are critical competitive factors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.